Coral Springs, FL (PRWEB) September 20, 2013
The producers of Health Briefs TV are pleased to announce that SFJ Pharmaceuticals will be featured in an upcoming segment on "Innovative Drug Development and Clinical Research Driving Improved Patient Care" as part of the show's Medical Minutes series.
Their value of pharmaceuticals is especially evident in the field of oncology, where the speed of development and availability of drugs may offer the first ever treatment, or have significant advantages over existing drugs. With the costs of developing a cancer drug reaching up to one billion dollars, however, many pharmaceutical companies are using a step-by-step approach. They first advance their most promising drugs for one cancer type, line of therapy or stage, and then advance for additional cancer types, lines of therapy or stages, thus delaying the time it takes for life-saving and life-enhancing to get into the hands or physicians and patients.
Additionally, drugs are first developed for the largest markets, like breast and lung cancer. Drugs for other cancer types, like thyroid and kidney, are not as aggressively developed. Years may go by while patients in need wait, without access to life-saving or life-enhancing drugs.
Pleasanton, California-headquartered SFJ Pharmaceuticals has developed a revolutionary model to overcome drug development challenges. The company captures the lost value for pharmaceutical companies and patients, by taking drugs which are proven in one type of cancer, and helping to accelerate them through clinical development for many different types and stages of cancer.
The five-minute Health Briefs TV segment will educate viewers on the importance of efficient drug development, and will feature the innovative model developed by SFJ Pharmaceuticals to make drugs available to more patients, sooner. The segment will highlight several of SFJ's partnerships, including Eisai Pharmaceuticals for Phase III development of their drug, Lenvatinib, to treat 131I-Refractory Differentiated Thyroid Cancer; Pfizer's drug, Dacomitinib, for first-line treatment of non-small cell lung cancer; and Pfizer's drug, Axitinib, for the adjuvant treatment of renal cell carcinoma. For more information about SFJ Pharmaceuticals, please visit http://www.sfj-pharma.com.
Read the full story at http://www.prweb.com/releases/health-briefs-tv-and-sfj/pharmaceuticals-seg/prweb11138064.htm.
Copyright©2012 Vocus, Inc.
All rights reserved